The medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
In one study, participants with insulin-intensive type 2 diabetes using MiniMed 780G (under investigational use) achieved an average 8.6% increase in time in range. They reached 84.9% time in range — well ahead of ADA’s 70% goal. The HbA1C reduction from 7.7% to 6.9% met ADA targets, too.
Separately, Medtronic reported data from the LENNY trial, also published in The Lancet Diabetes & Endocrinology. The multi-center trial evaluated MiniMed 780G in young children (ages 2-6) with type 1 diabetes in a home setting. Results demonstrated a 0.6% lower HbA1C and 9.9% higher time in range on MiniMed 780G compared to the baseline therapy. The study used manual mode or hybrid closed loop without autocorrections as the baseline.
Parents and caregivers also reported improved sleep quality and lower fear of hypoglycemia with the system used in auto mode with the SmartGuard CGM compared to manual mode.
“As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin,” said Dr. Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. “Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before.”
Medtronic plans to separate its Diabetes unit in the next 18 months. Read more about that here.
More on the Medtronic Diabetes studies
According to Medtronic, the ADA’s 2025 standards of care now endorse the use of automated insulin delivery for adults with insulin-intensive type 2 diabetes.
Medtronic’s system remains investigational for type 2 diabetes while the company awaits potential FDA approval. Insulet’s Omnipod 5 automated insulin delivery system became the first such system cleared for type 1 and type 2 diabetes last August. Tandem Diabetes care followed suit in February with its own FDA nod.
A 31-site, single-arm study evaluated MiniMed 780G with the Simplera Sync sensor in 236 patients with type 2 diabetes. The company reported promising results across all metrics, including time in range, time in tight range, and time above range compared to the run-in period where hybrid closed-loop (auto basal only) or open-loop delivery was used. Time below range remained stable, too.
For the LENNY trial, investigators evaluated 98 subjects across 12 centers in four countries. They saw significantly better glycemic management in auto mode and no hypoglycemic events, meaning it had an acceptable safety profile.
Participants in auto mode spent on average 145 minutes per day more in range than those in manual mode.
Medtronic aims to bring its MiniMed 780G system to the type 2 diabetes population of children under seven years old. It said it plans to work with global regulators to expand access to its technology for the type 2 population, plus a lower age indication for type 1.
“We’re hopeful that if the data continues to be strong, we will receive future indication expansion so the most vulnerable group, small children under 7 years, and their families can also benefit from this technology “, said Dr. Ohad Cohen, senior global medical affairs director, Medtronic Diabetes.
